# US 7,745,198 B2 · Method of producing macrolide compound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,745,198 B2
- Document ID: US7745198B2
- Status: Granted
- Kind: B2
- Application number: 10/532,412
- Filed: 2003-11-27
- Published: 2006-06-29
- Granted: 2010-06-29
- Earliest claimed: 2002-11-29
- Assignees: Mercian Corporation; Eisai R&D Management Co., Ltd.
- Inventors: Akifumi Okuda; Satoshi Yamamoto; Takashi Sakai; Susumu Takeda; Takashi Nakashima; Katsura Kaneko; Tomohiro Sameshima; Taira Kato; Naoto Kawamura
- Web page: https://patentgrep.com/patent/US7745198B2

## CPC

- C07D 407/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61K 31/336: having three-membered rings, e.g. oxirane, fumagillin
- A61P 35/00: Antineoplastic agents
- C12P 17/162: {Heterorings having oxygen atoms as the only ring heteroatoms, e.g. Lasalocid}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}

## Abstract

The present invention provides a novel method of producing the 12-membered ring macrolide compound 11107D having an antitumor activity by biological transformation. Starting material which is the 12-membered ring macrolide compound 11107B represented by the formula (I) is incubated in the presence of a strain belonging to the genus Mortierella, the genus Streptomyces or the family Micromonosporaceae (for example, Streptomyces sp. AB-1704 strain (FERM BP-8551)), each of which has the ability of transforming the 12-membered ring macrolide compound 11107B into a 11107D substance represented by the formula (II), or a preparation of its cultured myceha and oxygen, and then 11107D substance which is a target material is collected from the treating solution.

## Claims

### Claim 1

A method of producing the macrolide compound 11107D represented by the formula (II):
by a biological transformation method, wherein said method of producing the macrolide compound 11107D comprises the steps of:
providing the macrolide compound 11107B represented by the formula (I):
mixing the macrolide compound 11107B represented by the formula (I) with a strain having an ability of conducting the above-mentioned biological transformation method and belonging to the genus Mortierella, the genus Streptomyces or the family Micromonosporaceae or a preparation of its cultured mycelia;
incubating the mixture obtained in the preceding mixing step; and
collecting the macrolide compound 11107D represented by the formula (II) from the incubated solution obtained in the preceding incubating step.

### Claim 2 (depends on 1)

The production method according to claim 1, wherein the strain belonging to the genus Streptomyces is Streptomyces sp. AB-1704 strain (FERM BP-8551), A-1544 strain (FERM BP-8446) or A-1545 strain (FERM BP-8447).

### Claim 3

An isolated or purified culture of Streptomyces sp. AB-1704 strain (FERM BP-8551) having the ability of transforming the macrolide compound 11107B represented by formula (I)
into the macrolide compound 11107D represented by formula (II)